Immunity Clinical Trial
Official title:
A Clinical Study on The Effect of Probiotic Compound Powder (WONDERLAB) on The Immunity Improvement of Preschool Children (RCT)
Verified date | November 2023 |
Source | Shenzhen Precision Health Food Technology Co. Ltd., |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized controlled trial, to evaluate the effect of WONDERLAB Probiotic Compound Powder on improving immunity of preschool children
Status | Completed |
Enrollment | 140 |
Est. completion date | April 30, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 6 Years |
Eligibility | Inclusion Criteria: - Preschool children, male or female, 5 to 6 years old; - Those with weak constitution and easy to get sick: One of them can be satisfied: AGet cold = 3 times a year B Bronchitis or pneumonia =2 times per year C Rotavirus diarrhea =1 time per year - During the trial, participants agree not to take any drugs, supplements, or other dairy products containing probiotics; - During the trial, participants agree not to take any other prebiotic/bacterial drugs, supplements, or dairy products including yogurt drinks; - Willing to refrain from participating in other interventional clinical studies during the trial period; - Be able to fully understand the nature, purpose, benefits and possible risks and side effects of the research; - Willing to obey all test requirements and procedures; - Informed consent signed by parents or legal guardians. Exclusion Criteria: - Subject who is in the treatment of gastrointestinal diseases; - Subject who has lactose intolerance; - The subjects are currently suffering from other organic diseases that affect intestinal function, such as history of gastrointestinal resection, colonic or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, Hirschsprung's disease, scleroderma, anorexia nervosa, etc.; - Subjects have any of the following medical histories or clinically diagnosed diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases; - According to the judgment of the researchers, frequent use of drugs that may affect gastrointestinal function or the immune system; - Subjects who took laxatives or other digestive aids 2 weeks before the start of the study; - Consumed dairy products or other foods containing prebiotics/bacteria within 10 days before the start of the study; - PI believes that volunteers cannot fully cooperate with the trial arrangement. |
Country | Name | City | State |
---|---|---|---|
China | Wenan Wang | Jinhua | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Shenzhen Precision Health Food Technology Co. Ltd., |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rotavirus diarrhea Testing at baseline | Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 12 month | baseline(day 0) | |
Primary | Rotavirus diarrhea Testing at endpoint | Records of sick leave days, medical visits and hospitalization days due to rotavirus infection within past 168 days | endpoint( day 168) | |
Primary | Infection of the upper respiratory tract at baseline | Drug records of upper respiratory tract infection within past 12 months. | baseline(day 0) | |
Primary | Infection of the upper respiratory tract at endpoint | Drug records of upper respiratory tract infection within past 168 days. | endpoint ( day 168) | |
Secondary | Bristol Stool Chart | To evaluate samples of human feces based on the shape and consistency of the stool. | baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175) | |
Secondary | Faeces | sIgA ?16sRNA?SCFA?Fecal calprotectin | baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175) | |
Secondary | Saliva | sIgA testing | baseline(day 0)/interim ( day 84)/endpoint( day 168)/recession period( day 175) | |
Secondary | Pittsburgh sleep quality index | 18 items comprise 7 components, each of which is scored according to o~3 grade. The cumulative score of each component is the total score of PSQI, with a total score range of 0~2l. The higher the score, the worse the sleep quality. | baseline(day 0)/interim ( day 84)/endpoint( day 168) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02814617 -
The Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity
|
Phase 2/Phase 3 | |
Completed |
NCT02244372 -
Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity
|
N/A | |
Completed |
NCT00990002 -
Investigation of A Children's Beverage Containing Different Probiotics
|
N/A | |
Completed |
NCT00788021 -
Protective Immunity Project 01
|
N/A | |
Completed |
NCT01736787 -
Efficacy and Safety of Cauliflower Mushroom Extract on Promotion of Immunity
|
N/A | |
Recruiting |
NCT04579588 -
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
|
||
Completed |
NCT04798677 -
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
|
N/A | |
Completed |
NCT05162820 -
Impact of Solarplast® on Immunity in Active Smokers and Non-smokers
|
N/A | |
Completed |
NCT01657656 -
Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia
|
N/A | |
Recruiting |
NCT05117385 -
The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune)
|
N/A | |
Completed |
NCT05190237 -
the Efficacy and Safety of Fermented Soybean(Doenjang Powder) on Intestinal Microflora and Immune Enhancement.
|
N/A | |
Completed |
NCT04647071 -
Allium Extracts on the Incidence of Respiratory Infection Symptoms in Healthy Elderly Volunteers
|
N/A | |
Completed |
NCT04031222 -
Mechanisms of Inflammation, Immunity, Islet Cell and Intestinal Hormone Changes in Youth at Risk for Diabetes
|
||
Completed |
NCT04010331 -
Efficacy and Safety of Nokyong Mixture Extract(CME-PI) on Promotion of Immunity
|
N/A | |
Completed |
NCT03067714 -
A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy
|
Phase 3 | |
Completed |
NCT04664309 -
Understanding Immunity to the COVID-19 Vaccines
|
||
Withdrawn |
NCT06121362 -
Effect of Protocatechuic Acid on Biochemical Markers of Immunity Status in Healthy Adults
|
N/A | |
Recruiting |
NCT02166931 -
BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition
|
N/A | |
Recruiting |
NCT00645996 -
The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants
|
N/A | |
Completed |
NCT03336086 -
Effect of Weight Reduction on Immunity
|
Phase 3 |